How often do TRUS “blind” biopsies miss higher grade cancer?

How often do TRUS “blind” biopsies miss higher grade cancer?

Urologist Bela Denes Transcript

Title: How often do TRUS “blind” biopsies miss higher grade prostate cancer?

So the Oncotype DX Genomic Prostate score is a test that is run on the tumor itself. We extract the RNA, in other words the genetic information within that tumor, and by analyzing that genomic information, we’re able to predict whether the tumor that’s sampled is actually representative of what’s in the prostate, or whether there’s a high suspicion of high grade disease sort of lurking somewhere else within the gland, it just was missed by the small biopsy needle.

The Oncotype DX Genomic Prostate test was developed specifically to address some of the issues of random biopsies and that is based on the random nature of the biopsies … you don’t know if it happens to be sampling the most aggressive part of the tumor, or if you’ve missed the tumor altogether or if you’re relying on the biopsy from the lower grade tumor or the more innocent part of the tumor, and then basing treatment recommendations based on that, where if there’s a high grade tumor lurking someplace else within the prostate.

So what we do is narrow the likelihood that you’re sort of harboring high-grade disease or raise the likelihood that in fact the biopsy which shows that you have low-grade cancer or Gleason 6 cancer is actually representative of what’s in the prostate.

Title: Studies show 20 – 50% of TRUS “blind” biopsies miss higher grade prostate cancer

Urologist Bela Denes discusses how TRUS biopsies often miss higher grade cancer, leading to error rates in Gleason scores.
Urologist Bela Denes

Board certified urologist Bela Denes trained at Washington University in St. Louis, Missouri. After 25 years of clinical and academic experience, Dr. Denes now leads the Genomic Health Medical Affairs team as the Senior Director of Urology. 
Video reviewed and approved by Dr. Denes, August 1, 2015